Swedish Orphan Biovitrum AB/ SE0000872095 /
9/13/2024 5:17:57 PM | Chg. +6.90 | Volume | Bid8/8/2024 | Ask8/22/2024 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
326.10SEK | +2.16% | 5,521 Turnover: 1.78 mill. |
-Bid Size: - | -Ask Size: - | 115.8 bill.SEK | - | 43.75 |
GlobeNewswire
8/8
Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
7/30
ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
GlobeNewswire
5/24
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Act...
GlobeNewswire
5/15
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at ...
GlobeNewswire
5/9
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
GlobeNewswire
5/6
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
5/6
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLON...
GlobeNewswire
5/1
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on...
GlobeNewswire
4/4
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination wit...
GlobeNewswire
4/3
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
GlobeNewswire
3/13
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business U...
GlobeNewswire
3/6
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
GlobeNewswire
3/6
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March...